Business Context and Reporting Period
Company: PMGC Holdings Inc. (Nasdaq: ELAB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2025
Reporting Period: Events occurring on May 12, 2025, with a press release issued May 13, 2025.
Context: The filing reports on two material agreements entered into by Northstrive Biosciences Inc., a wholly owned subsidiary of PMGC Holdings, focusing on the expansion and clarification of licensing rights in the animal health sector.
Key Financial Metrics
This Form 8-K is a current report regarding material definitive agreements and does not contain audited financial statements, revenue figures, profit data, cash flow statements, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreements
- Second Amendment to License Agreement (MOA Life Plus Co., Ltd.):
- Amends the Original Agreement (April 30, 2024) and First Amendment (March 2025) regarding the "Animal Health Field."
- Clarifies that specific obligations (Sections 3.5, 3.6, 4.3, 7.1-7.4, 8.2(a), 9.3) do not apply to the Animal Health Field.
- Limits Northstrive's payment obligations to MOA for this field to: (a) royalties on directly-earned net sales in the territory, and (b) remittance of value from sublicensees.
- Binding Term Sheet (Modulant Biosciences LLC):
- Outlines terms for a future exclusive, worldwide licensing agreement (excluding Korea) for animal health uses, including feed additives.
- Grants Modulant exclusive rights to sub-license the intellectual property globally.
- Covers specific U.S. Patents and Applications (e.g., U.S. Patent 8,470,551).
- Establishes a revenue-sharing model where Northstrive receives a percentage of revenues from sublicensing and commercial activities, subject to a tiered royalty rate structure based on a dollar limit.
- Includes provisions for co-ownership of new IP developed by Modulant.
Guidance, Outlook, and Risks
Management Commentary: The agreements indicate a strategic focus on commercializing intellectual property in livestock and veterinary markets through partnerships. The Term Sheet with Modulant establishes a framework for collaboration, regulatory cooperation, and commercialization oversight.
Risks and Contingencies:
- The Term Sheet is not a definitive agreement; final terms are subject to the execution of a definitive licensing agreement.
- Financial obligations are contingent on future sales and sublicensing activities.
- Portions of the attached exhibits (Exhibits 10.1 and 10.2) have been redacted.
Investor Verification Checklist
- Verify the execution of the definitive licensing agreement with Modulant Biosciences LLC, as the current Term Sheet is not binding on all terms.
- Review the full text of the Second Amendment (Exhibit 10.1) to understand the specific exclusions of obligations for the Animal Health Field.
- Monitor the commercialization progress and revenue generation from the Modulant partnership to assess the tiered royalty structure.
- Confirm the status of the upstream license agreement obligations that flow through to the new agreements.